Insiders who reported open-market trades in the last 12 months at the companies Carmine N. Stengone files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
Daniel S. Lorrain - $1.04M in CTNM purchases and sales in the last 12 months
Tim Watkins - $279K in CTNM purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Carmine N. Stengone is a corporate insider, tracked as CEO and President, Director of Contineum Therapeutics, Inc. (CTNM). InsiderAlpha holds 8 primary Form 4 filings for them, the earliest from 2026, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Carmine N. Stengone submitted recently?
2 primary Form 4 filings in the last 90 days, covering 1 company.
Has Carmine N. Stengone been buying or selling stock?
Recorded transactions: 0 open-market purchases and 7 open-market sales ($401K) across all tracked filings.
Carmine N. Stengone is CEO and President, Director of Contineum Therapeutics, Inc. (CTNM). 8 SEC Form 4 filings on record, most recently on 8 September 2026. Most recent open-market trade: sold $41K of CTNM on 8 September 2026. Lifetime open-market sales: $401K.
Recent transactions
15
The latest 15 SEC Form 4 transactions reported by Carmine N. Stengone.
InsiderAlpha's records for Carmine N. Stengone go back to 2026: 8 primary Form 4 filings, an average of 8.0 per year. 23 recorded transactions carry a Rule 10b5-1 plan flag. This identifies the marked transactions as reported under a trading plan; it does not establish the plan status of unmarked transactions.
